Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
Hypocretin-1/orexin A participates in wakefulness/autonomic regulation through orexin receptors.
Evidence and critical reading
Reported scientific and empirical uses
Sleep and circadian rhythms
Investigated intranasally in narcolepsy; community cognitive promotion extends beyond those experiments.
Human evidence
A 14-patient crossover study evaluated one intranasal exposure and REM/attention variables; a 10-healthy-man pilot showed sympathetic changes. Neither establishes chronic home use.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A 14-patient crossover study evaluated one intranasal exposure and REM/attention variables; a 10-healthy-man pilot showed sympathetic changes. Neither establishes chronic home use.
A 14-patient crossover study evaluated one intranasal exposure and REM/attention variables; a 10-healthy-man pilot showed sympathetic changes. Neither establishes chronic home use.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
435 nmol · Single studied exposure
- Frequency
- One exposure in a crossover trial
- Duration
- Acute
- Route
- Intranasal
- Context
- 14 narcolepsy patients; do not convert nmol to mg without verified structure.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID24406723 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Autonomic activation matters even if a pilot does not change blood pressure/heart rate; long-term safety/interactions remain undefined.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID24406723 · Randomized controlled trial
Narcolepsy.
One intranasal exposure, crossover.
REM/attention changes in an acute experiment.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 14
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Orexin A · 79 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07830303 · Daridorexant for Sleep Disturbance in Adults With Liver CirrhosisRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT06679062 · Suvorexant for Treatment of AUD and PTSDRegistry status: RecruitingLast update posted: October 14, 2026Query verification: October 16, 2026
NCT07407400 · Lemborexant for Sleep and Delirium Prevention in Elderly ICU PatientsRegistry status: RecruitingLast update posted: October 8, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID24406723
Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC.
October 16, 2026
- PMID35044844
Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans.
Meusel M, Voß J, Krapalis A, Machleidt F, Vonthein R, Hallschmid M, Sayk F.
October 16, 2026
- SEARCH-PUBMED-orexin-a
PubMed/MED targeted search: TITLE_ABS:"intranasal orexin-A" AND TITLE_ABS:narcolepsy
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026